A Phase I-II Study of NBTXR3 Activated by Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers
Phase of Trial: Phase I/II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Hafnium oxide (Primary) ; Hafnium oxide (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nanobiotix
- 18 Sep 2019 According to a Nanobiotix media release, results from the phase 1 part of the study were presented at the ASTRO 2019 Annual Meeting.
- 18 Sep 2019 According to a Nanobiotix media release, more 3 patients are enrolled and recruitment in this study is expected to be complete in Q4 2019. Results from this study is expected in Q1 2020.
- 18 Sep 2019 Results (n=17) presented in a Nanobiotix media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History